Table 3.
Medication use in moderate‐to‐severe PsO+PsA patients and matched controlsa
| Moderate‐to‐severe PsO+PsA patients (n = 1,230) | Controls (n = 1,230) | Unadjusted P (patients vs. controls)b | OR/IRR (95% CI) (patients/controls)c | Adjusted P (patients vs. controls)c | |
|---|---|---|---|---|---|
| All‐cause medication | |||||
| Any medication filled, no. (%) | 1,229 (99.9) | 939 (76.3) | < 0.0001d | N/A | N/A |
| No. of distinct medications filled, mean ± SD | 12.77 ± 8.69 | 5.61 ± 6.45 | < 0.0001d | 2.3 (2.1–2.4) | < 0.0001d |
| Selected comorbidity‐related medication | |||||
| Any prescription filled, no. (%) | 781 (63.5) | 528 (42.9) | < 0.0001d | 2.5 (2.1–3.0) | < 0.0001d |
| No. of distinct medications filled, mean ± SD | 1.52 ± 2.11 | 1.11 ± 2.06 | < 0.0001d | 1.5 (1.3–1.7) | < 0.0001d |
| Antidepressants | |||||
| Any prescription filled, no. (%) | 352 (28.6) | 190 (15.4) | < 0.0001d | 2.1 (1.7–2.7) | < 0.0001d |
| No. of distinct medications filled, mean ± SD | 0.55 ± 1.07 | 0.30 ± 0.86 | < 0.0001d | 1.9 (1.5–2.3) | < 0.0001d |
| Antidiabetic drugs | |||||
| Any prescription filled, no. (%) | 146 (11.9) | 91 (7.4) | 0.0001d | 1.7 (1.2–2.4) | 0.0019d |
| No. of distinct medications filled, mean ± SD | 0.29 ± 0.93 | 0.20 ± 0.86 | 0.0062d | 1.5 (1.1–2.1) | 0.0164e |
| Cardiovascular drugs | |||||
| Any prescription filled, no. (%) | 645 (52.4) | 444 (36.1) | < 0.0001d | 2.2 (1.8–2.6) | < 0.0001d |
| No. of distinct medications filled, mean ± SD | 2.36 ± 2.91 | 1.61 ± 2.76 | < 0.0001d | 1.4 (1.2–1.6) | < 0.0001d |
Medication use was measured during the 12‐month study period. PsO = psoriasis; PsA = psoriatic arthritis; OR = odds ratio; IRR = incidence rate ratio; 95% CI = 95% confidence interval; N/A = not applicable.
Univariate comparison was made using McNemar's tests for ≥1 medication filled and Wilcoxon's signed rank tests for number of distinct medications filled.
ORs and P values were calculated for any medication filled from conditional logistic regression. IRRs and P values were calculated for number of distinct medications filled from negative binomial model with generalized estimating equation. All models controlled for age, sex, geographic region, index year, insurance type, individual non–PsO/PsA‐related comorbidities, and modified Charlson Comorbidity Index calculated based on non–PsO/PsA‐related comorbidities. ORs >1 and IRRs >1 indicate an increased risk and incidence rate, respectively, for PsO+PsA patients compared with controls.
Significance at 0.01 level.
Significance at 0.05 level.